GLP-1 Market
LLY $1354.00 ▼ -0.8% NVO $40.31 ▲ +0.0% PFE $29.39 ▼ -1.6% VKTX $26.84 ▲ +4.1% KLRA $12.97 ▲ +6.6% GPCR $20.35 ▲ +6.7% RHHBY $59.37 ▼ -0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GC012F

GC012F

Company
Gracell Biotechnologies (Shanghai) Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
16 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

16 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 7, 2026

Find a Clinical Trial Near Me

See recruiting studies for GC012F and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05850234

    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

    Not yet reported, Not yet reported AstraZeneca 232 participants Est. completion 2029-01-25 36 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05858684

    Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

    Not yet reported RenJi Hospital 18 participants Est. completion 2029-06-10 1 site Stand-alone
    Other conditions: CAR-T Cell Therapy
    View official trial listing →
  • Recruiting NCT NCT06235229

    A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Gracell Biotechnologies (Shanghai) Co., Ltd. 110 participants Est. completion 2026-03-02 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06897930

    A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

    Not yet reported, Not yet reported AstraZeneca 150 participants Est. completion 2029-05-01 20 sites Stand-alone
    Other conditions: Lupus Erythematosus, Systemic
    View official trial listing →
  • Recruiting NCT NCT07058298

    GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

    Not yet reported Daishi Tian 6 participants Est. completion 2027-09-10 1 site Stand-alone
    Other conditions: Generalized Myasthenia Gravis (gMG)
    View official trial listing →
  • Recruiting NCT NCT07073547

    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    Not yet reported AstraZeneca 40 participants Est. completion 2028-05-26 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07081646

    A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

    Not yet reported, Not yet reported Alexion Pharmaceuticals, Inc. 91 participants Est. completion 2031-02-14 18 sites Stand-alone
    Other conditions: Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07086404

    GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

    Not yet reported Daishi Tian 12 participants Est. completion 2029-09-15 1 site Stand-alone
    Other conditions: Idiopathic Inflammatory Myopathy (IIM)
    View official trial listing →
  • Recruiting NCT NCT07224373

    An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

    Not yet reported AstraZeneca 24 participants Est. completion 2028-12-12 19 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT07250269

    Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

    Not yet reported Gracell Biotechnologies (Shanghai) Co., Ltd. 12 participants Est. completion 2028-11-24 9 sites Stand-alone
    Other conditions: Relapsed/Refractory AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07295847

    A Study of AZD0120 in Autoimmune Diseases

    Not yet reported, Not yet reported AstraZeneca 27 participants Est. completion 2028-02-22 25 sites Stand-alone
    Other conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT07303790

    This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

    Not yet reported Daishi Tian 9 participants Est. completion 2028-12-10 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT07350837

    CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

    Not yet reported Tongji Hospital 12 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Highly Sensitized Patients Awaiting Kidney Transplant
    View official trial listing →
  • Recruiting NCT NCT07391657

    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

    Not yet reported AstraZeneca 508 participants Est. completion 2030-07-29 143 sites Stand-alone
    Other conditions: Relapsed Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07735637

    A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

    Not yet reported AstraZeneca 750 participants Est. completion 2039-11-17 114 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma (NDMM)
    View official trial listing →
  • Recruiting NCT NCT07764978

    Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

    Not yet reported AstraZeneca 750 participants Est. completion 2034-05-12 124 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04236011

    BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

    Not yet reported Shanghai Changzheng Hospital 15 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04617704

    BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

    Not yet reported Shanghai Changzheng Hospital 15 participants Est. completion 2022-02-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04935580

    Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

    Not yet reported, Not yet reported Shanghai Changzheng Hospital 20 participants Est. completion 2023-07-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05412329

    Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

    Not yet reported Shanghai Changzheng Hospital 9 participants Est. completion 2024-06-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05840107

    Study of FasT CAR-T GC012F Injection NDMM Patients

    Not yet reported Shanghai Changzheng Hospital 18 participants Est. completion 2025-09-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05846347

    Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

    Not yet reported Zhejiang University 15 participants Est. completion 2025-04-19 1 site Stand-alone
    Other conditions: CAR-T
    View official trial listing →
  • Withdrawn NCT NCT06419166

    An Exploratory Clinical Study of GC012F Injection for Refractory gMG

    Not yet reported Zhejiang University Est. completion 2027-10-01 1 site Stand-alone
    Other conditions: Refractory Generalized Myasthenia Gravis
    View official trial listing →
  • Active, not recruiting NCT NCT06530849

    A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

    Not yet reported, Not yet reported Gracell Biotechnologies (Shanghai) Co., Ltd. 20 participants Est. completion 2027-02-01 2 sites Stand-alone
    Other conditions: Refractory Systemic Lupus Erythematosus
    View official trial listing →
  • Not yet recruiting NCT NCT06759948

    An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

    Not yet reported Chongbo Zhao 18 participants Est. completion 2027-09-10 1 site Stand-alone
    Other conditions: Generalized Myasthenia Gravis (gMG)
    View official trial listing →
  • Not yet recruiting NCT NCT07072884

    GC012F in Patients With Autoimmune Diseases

    Not yet reported Qiong Fu 15 participants Est. completion 2029-03-31 Stand-alone
    Other conditions: Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
    View official trial listing →
  • Withdrawn NCT NCT07315503

    An Open-label Study of GC012F in Rheumatoid Arthritis.

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China Est. completion 2041-01-15 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Withdrawn NCT NCT07364487

    This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

    Not yet reported Huashan Hospital Est. completion 2026-03-25 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Not yet recruiting NCT NCT07790575

    Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

    Not yet reported Saurabh Dahiya 16 participants Est. completion 2041-07 1 site Stand-alone
    Other conditions: Cytopenia
    View official trial listing →
  • Not yet recruiting NCT NCT07833046

    Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection

    RenJi Hospital 40 participants Est. completion 2039-08-21 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: GC012F, GC012F Injection, AZD0120

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.